Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(3):413–417. doi: 10.1038/bjc.1996.374

Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.

C F Sier 1, F J Kubben 1, S Ganesh 1, M M Heerding 1, G Griffioen 1, R Hanemaaijer 1, J H van Krieken 1, C B Lamers 1, H W Verspaget 1
PMCID: PMC2074643  PMID: 8695357

Abstract

Proteinases are involved in tumour invasion and metastasis. Several matrix metalloproteinases (MMPs) have been shown to be increased in various human carcinomas. We assessed the levels of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) in 50 gastric carcinomas and corresponding mucosa using quantitative gelatin zymography. Both MMP levels were significantly enhanced in gastric carcinomas compared with adjacent mucosal tissue, showed a relatively poor intercorrelation and no relation was found with histopathological carcinoma classifications according to Laurén, WHO and tumour-node-metastasis (TNM). Cox's multivariate proportional hazards analyses revealed that high carcinomatous MMP values are of prognostic significance for a poor overall survival of the patients, independent of the major clinicopathological parameters.

Full text

PDF
413

Images in this article

414Figure 1
on p.414

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergmann U., Michaelis J., Oberhoff R., Knäuper V., Beckmann R., Tschesche H. Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem. 1989 Jun;27(6):351–359. doi: 10.1515/cclm.1989.27.6.351. [DOI] [PubMed] [Google Scholar]
  2. Bergmann U., Michaelis J., Oberhoff R., Knäuper V., Beckmann R., Tschesche H. Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem. 1989 Jun;27(6):351–359. doi: 10.1515/cclm.1989.27.6.351. [DOI] [PubMed] [Google Scholar]
  3. Duffy M. J., Blaser J., Duggan C., McDermott E., O'Higgins N., Fennelly J. J., Tschesche H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer. 1995 May;71(5):1025–1028. doi: 10.1038/bjc.1995.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Duffy M. J., Blaser J., Duggan C., McDermott E., O'Higgins N., Fennelly J. J., Tschesche H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer. 1995 May;71(5):1025–1028. doi: 10.1038/bjc.1995.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988 Mar 1;48(5):1348–1349. [PubMed] [Google Scholar]
  6. Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res. 1988 Mar 1;48(5):1348–1349. [PubMed] [Google Scholar]
  7. Duffy M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992 May;10(3):145–155. doi: 10.1007/BF00132746. [DOI] [PubMed] [Google Scholar]
  8. Duffy M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992 May;10(3):145–155. doi: 10.1007/BF00132746. [DOI] [PubMed] [Google Scholar]
  9. Emmert-Buck M. R., Roth M. J., Zhuang Z., Campo E., Rozhin J., Sloane B. F., Liotta L. A., Stetler-Stevenson W. G. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol. 1994 Dec;145(6):1285–1290. [PMC free article] [PubMed] [Google Scholar]
  10. Emmert-Buck M. R., Roth M. J., Zhuang Z., Campo E., Rozhin J., Sloane B. F., Liotta L. A., Stetler-Stevenson W. G. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol. 1994 Dec;145(6):1285–1290. [PMC free article] [PubMed] [Google Scholar]
  11. Ganesh S., Sier C. F., Griffioen G., Vloedgraven H. J., de Boer A., Welvaart K., van de Velde C. J., van Krieken J. H., Verheijen J. H., Lamers C. B. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 1994 Aug 1;54(15):4065–4071. [PubMed] [Google Scholar]
  12. Ganesh S., Sier C. F., Griffioen G., Vloedgraven H. J., de Boer A., Welvaart K., van de Velde C. J., van Krieken J. H., Verheijen J. H., Lamers C. B. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 1994 Aug 1;54(15):4065–4071. [PubMed] [Google Scholar]
  13. Grigioni W. F., D'Errico A., Fortunato C., Fiorentino M., Mancini A. M., Stetler-Stevenson W. G., Sobel M. E., Liotta L. A., Onisto M., Garbisa S. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol. 1994 Feb;7(2):220–225. [PubMed] [Google Scholar]
  14. Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W. J., van Hinsbergh V. W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 1993 Dec 15;296(Pt 3):803–809. doi: 10.1042/bj2960803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hasui Y., Marutsuka K., Suzumiya J., Kitada S., Osada Y., Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer. 1992 Apr 1;50(6):871–873. doi: 10.1002/ijc.2910500607. [DOI] [PubMed] [Google Scholar]
  16. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312. doi: 10.1055/s-2007-1002624. [DOI] [PubMed] [Google Scholar]
  17. Kleiner D. E., Stetler-Stevenson W. G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994 May 1;218(2):325–329. doi: 10.1006/abio.1994.1186. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Matrisian L. M. The matrix-degrading metalloproteinases. Bioessays. 1992 Jul;14(7):455–463. doi: 10.1002/bies.950140705. [DOI] [PubMed] [Google Scholar]
  20. McDonnell S., Navre M., Coffey R. J., Jr, Matrisian L. M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4(6):527–533. doi: 10.1002/mc.2940040617. [DOI] [PubMed] [Google Scholar]
  21. Naito K., Kanbayashi N., Nakajima S., Murai T., Arakawa K., Nishimura S., Okuyama A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994 Sep 1;58(5):730–735. doi: 10.1002/ijc.2910580518. [DOI] [PubMed] [Google Scholar]
  22. Nekarda H., Schmitt M., Ulm K., Wenninger A., Vogelsang H., Becker K., Roder J. D., Fink U., Siewert J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994 Jun 1;54(11):2900–2907. [PubMed] [Google Scholar]
  23. Pedersen H., Brünner N., Francis D., Osterlind K., Rønne E., Hansen H. H., Danø K., Grøndahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994 Sep 1;54(17):4671–4675. [PubMed] [Google Scholar]
  24. Poulsom R., Pignatelli M., Stetler-Stevenson W. G., Liotta L. A., Wright P. A., Jeffery R. E., Longcroft J. M., Rogers L., Stamp G. W. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 1992 Aug;141(2):389–396. [PMC free article] [PubMed] [Google Scholar]
  25. Sier C. F., Verspaget H. W., Griffioen G., Verheijen J. H., Quax P. H., Dooijewaard G., De Bruin P. A., Lamers C. B. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology. 1991 Dec;101(6):1522–1528. doi: 10.1016/0016-5085(91)90387-z. [DOI] [PubMed] [Google Scholar]
  26. Wang X., Fu X., Brown P. D., Crimmin M. J., Hoffman R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726–4728. [PubMed] [Google Scholar]
  27. Yamagata S., Yoshii Y., Suh J. G., Tanaka R., Shimizu S. Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Lett. 1991 Jul 26;59(1):51–55. doi: 10.1016/0304-3835(91)90135-5. [DOI] [PubMed] [Google Scholar]
  28. Zucker S., Lysik R. M., Zarrabi M. H., Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 Jan 1;53(1):140–146. [PubMed] [Google Scholar]
  29. Zucker S., Mancuso P., DiMassimo B., Lysik R. M., Conner C., Wu C. L. Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays. Clin Exp Metastasis. 1994 Jan;12(1):13–23. doi: 10.1007/BF01784329. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES